文献速递介入腹部CTDSA

基于锥形束CT的放射性药物洗脱微球经动脉化疗栓塞术后药物剂量空间预测:土拨鼠肝细胞癌模型研究

Cone-Beam Computed Tomography-Based Spatial Prediction of Drug Dose After Transarterial Chemoembolization Using Radiopaque Drug-Eluting Beads in Woodchuck Hepatocellular Carcinoma.
PubMed 文献 · Invest Radiol · 2022-03-04

在土拨鼠肝细胞癌模型(N=5)中,利用锥形束CT上放射性药物洗脱微球的密度建立模型,预测经动脉化疗栓塞术后肿瘤内多柔比星剂量,并与高压液相色谱测得的多柔比星水平相关(相关系数0.96);未纳入模型开发的肿瘤切片预测准确,均方根误差为0.08 mg多柔比星;含微球簇的血管周围药物渗透范围大于单个微球。

要点

  • 锥形束CT上药物洗脱微球碘含量与肿瘤标本多柔比星量呈正线性相关(0.96)。
  • 未纳入模型开发的肿瘤切片多柔比星水平预测准确,均方根误差0.08 mg。
  • 含微球簇的血管周围多柔比星渗透浓度和距离大于单个微球。

核心结论

  • 在土拨鼠肝细胞癌模型中,利用锥形束CT上药物洗脱微球的放射性不透性作为替代标志物,可估算经动脉化疗栓塞术中递送的药物剂量;含微球簇的血管周围多柔比星渗透最大。

研究设计与样本

  • 动物实验研究,使用土拨鼠肝细胞癌模型(N=5),行经动脉化疗栓塞术,采用载多柔比星的药物洗脱微球(70-150 μm,LC Bead LUMI);栓塞后45分钟切除肝脏,立即冷冻并用肝脏专用3D打印切片模具切割;通过高压液相色谱测量肿瘤标本多柔比星水平,并与原型锥形束CT栓塞治疗计划软件测得的微球碘含量进行相关分析;通过荧光显微镜评估多柔比星渗透,荧光强度经校准标准转换为多柔比星浓度。

关键影像表现/征象

  • 锥形束CT上药物洗脱微球碘含量与肿瘤标本中多柔比星量呈正线性相关(相关系数0.96)。
  • 未纳入模型开发的肿瘤切片多柔比星水平预测准确,均方根误差为0.08 mg多柔比星。
  • 洗脱多柔比星的肿瘤渗透形成浓度梯度,药物含量随距含微球血管距离增加而降低。
  • 含微球簇的血管周围药物渗透大于单个微球,较高多柔比星浓度延伸至更远处。

诊断标准与关键数值

  • 采用半自动强度阈值法在锥形束CT上实现药物洗脱微球的稳定分割。
  • 锥形束CT测得微球碘含量与肿瘤标本多柔比星量的正线性相关系数为0.96。
  • 未纳入模型开发的肿瘤切片多柔比星水平预测均方根误差为0.08 mg多柔比星。

临床应用与阅片要点

  • 术中基于锥形束CT估算肿瘤内药物剂量空间分布,可能实现实时调整药物洗脱微球递送。
  • 含微球簇的血管周围多柔比星渗透大于单个微球,阅片时可关注微球聚集方式与药物覆盖范围的关系。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The aims of this study were to develop a model to estimate drug dose delivered to tumors after transarterial chemoembolization (TACE) with radiopaque drug-eluting beads (DEBs) based on DEB density on cone-beam computed tomography (CT) and to evaluate drug penetration into tissue in a woodchuck hepatoma model.

MATERIALS AND METHODS: Transarterial chemoembolization was performed in woodchucks with hepatocellular carcinoma (N = 5) using DEBs (70-150 μm, LC Bead LUMI) loaded with doxorubicin. Livers were resected 45 minutes after embolization, immediately frozen, and cut using liver-specific, 3D-printed sectioning molds. Doxorubicin levels in tumor specimens were measured by high-performance liquid chromatography and correlated with DEB iodine content that was measured using prototype cone-beam CT-based embolization treatment planning software. Doxorubicin penetration into tissue surrounding DEBs was assessed by fluorescence microscopy of tumor sections. Fluorescence intensity was converted into doxorubicin concentration using calibration standards. Intensity-thresholded color heatmaps were generated representing extravascular drug penetration.

RESULTS: Consistent segmentation of DEBs on cone-beam CT was achieved using a semiautomated intensity thresholding method. A positive linear correlation (0.96) was found between DEB iodine content measured on cone-beam CT and the amount of doxorubicin measured in tumor specimens. Prediction of doxorubicin levels in tumor sections that were not included in model development was accurate, with a root-mean-square error of 0.08 mg of doxorubicin. Tumor penetration of eluted doxorubicin resulted in concentration gradients where drug content decreased with increasing distance from blood vessels containing DEBs. Drug penetration was greater for blood vessels containing DEB clusters compared with single DEB, with higher doxorubicin concentrations extending further away from the vessels.

CONCLUSIONS: Estimation of drug dose delivered during transarterial chemoembolization in a woodchuck hepatocellular carcinoma model was possible using DEB radiopacity on cone-beam CT as a surrogate marker. Doxorubicin penetration was greatest adjacent to vessels containing DEB clusters compared with single DEB. Intraprocedural estimation of the spatial distribution of drug dose within the tumor could enable real-time adjustments to DEB delivery, to maximize treatment coverage or identify regions of tumor at risk for undertreatment.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Mikhail, Pritchard, Negussie, et al. Cone-Beam Computed Tomography-Based Spatial Prediction of Drug Dose After Transarterial Chemoembolization Using Radiopaque Drug-Eluting Beads in Woodchuck Hepatocellular Carcinoma. Invest Radiol. 2022. PMID: 35239613. doi:10.1097/RLI.0000000000000864

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。